2020 Oct...
The South African Health Products Regulatory Authority (SAHPRA) wishes to alert healthcare professionals about the risk of serious heart problems, seizures, coma and death associated with the use of high doses of diphenhydramine-containing medicines. An online challenge known as “the Benadryl Challenge” has recently been...
Pharmacare, in consultation with the South African Health Products Regulatory Authority (SAHPRA) would like to warn healthcare professionals about an increase of adverse events/side effects associated with the introduction of Eltroxin New Formulation® and a call for therapeutic drug monitoring in patients using or switched...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of an increased risk of subclinical acute nephritis associated with the use of PPIs leading to chronic renal inflammation and reduced renal function....
Sanofi-Aventis South Africa (Pty) Ltd and Adcock Ingram Ltd in agreement with the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about the risk of drug induced liver injury (DILI) associated with the use of metamizole-containing medicines...
SAHPRA is pleased to announce the launch of the Med Safety App. The Med Safety App is a mobile application (App) that is designed to simplify and promote the reporting of suspected adverse drug reactions (ADRs), including adverse events following immunisation (AEFIs) by both the...
Janssen Pharmaceutica (Pty) Ltd, as directed by the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about the risk of thrombosis in combination with thrombocytopenia, associated with the use of COVID-19 Vaccine Janssen...
MSD (Pty) Ltd, as directed by the South African Health Products Regulatory (SAHPRA) would like to inform healthcare professionals about the risk of dopamine dysregulation syndrome (DDS) associated with the use of dopamine containing medicines in the treatment of Parkinson’s Disease. The Professional...
Novartis as directed by the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about the increased incidence of intraocular inflammation (IOI) and related adverse events including retinal vasculitis (RV) and retinal vascular occlusion (RO) associated with (brolucizumab) when administered at 4...
Janssen Pharmaceutica (Pty) Ltd, as directed by the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about new safety information that has resulted in contraindication of the COVID-19 Vaccine Janssen in individuals with a history of Capillary Leak Syndrome (CLS). ...